Valuation : Lipocine Inc.

Market Cap 1.79Cr 1.54Cr 1.45Cr 1.32Cr 2.49Cr 170.98Cr 2.49Cr 17Cr 6.69Cr 86Cr 6.72Cr 6.57Cr 286.19Cr P/E 2026 *
-1.4x
P/E 2027 * -1.32x
Enterprise Value 1.79Cr 1.54Cr 1.45Cr 1.32Cr 2.49Cr 170.98Cr 2.49Cr 17Cr 6.69Cr 86Cr 6.72Cr 6.57Cr 286.19Cr EV / Sales 2026 *
23.7x
EV / Sales 2027 * 16.4x
Free-Float
95.49%
Yield 2026 *
-
Yield 2027 * -
1 day-2.69%
1 week+3.83%
Current month+2.36%
1 month+4.83%
3 months-3.56%
6 months-78.21%
Current year-72.98%
1 week 2.05
Extreme 2.0501
2.3
1 month 2.02
Extreme 2.02
2.3
Current year 1.81
Extreme 1.81
12.37
1 year 1.81
Extreme 1.81
12.37
3 years 1.81
Extreme 1.81
12.37
5 years 1.81
Extreme 1.81
32.13
10 years 1.81
Extreme 1.81
100.3
Manager TitleAgeSince
Chief Executive Officer 69 01/01/1997
Chief Tech/Sci/R&D Officer 56 01/12/2022
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 69 08/01/2014
Director/Board Member 58 01/01/2003
Chairman 73 20/04/2026
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Free

Director

2,000 0.0243%
03/06/26 Free

Director

1,764 0.0214%
03/06/26 Free

Chairman

1,764 0.0214%
Change 5-day change 1-year change 3-year change Capi.($)
-2.69%+3.83%-25.43%-47.07% 1.79Cr
-1.59%-3.35%+52.37%+93.70% 6.95TCr
-1.34%-0.75%+48.21%+91.86% 6.5TCr
+0.30%-0.69%+52.56%+10.23% 2.65TCr
-2.35%-5.75%-12.90%+448.54% 2.59TCr
-8.37%-12.43%+2.08%-16.71% 2.56TCr
-0.96%+10.36%+283.06%+436.50% 2.02TCr
-0.51%+0.23%+35.77%-18.70% 2TCr
-1.91%-4.37%+13.28%+535.19% 1.57TCr
-1.47%+0.68%+45.51%+143.08% 1.35TCr
Average -2.09%-1.06%+49.45%+167.66% 2.82TCr
Weighted average by Cap. -1.93%-1.50%+53.72%+151.50%

Financials

2026 *2027 *
Net sales 8L 6L 6L 6L 10.47L 7.2Cr 10.5L 72.23L 28.18L 3.64Cr 28.29L 27.67L 12Cr 10.9L 9L 9L 8L 15.14L 10Cr 15.19L 1.04Cr 40.76L 5.26Cr 40.92L 40.03L 17Cr
Net income -1.25Cr -1.08Cr -1.01Cr -92.19L -1.74Cr -119.47Cr -1.74Cr -12Cr -4.68Cr -60Cr -4.69Cr -4.59Cr -199.97Cr -1.91Cr -1.65Cr -1.54Cr -1.41Cr -2.66Cr -182.64Cr -2.66Cr -18Cr -7.15Cr -92Cr -7.17Cr -7.02Cr -305.71Cr
Net Debt - -
Logo Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Employees
14
Date Price Change Volume
28/26/28 $2.170 -2.69% 19,546
27/26/27 $2.230 +3.72% 41,550
26/26/26 $2.150 0.00% 1,06,047
25/26/25 $2.150 +4.37% 11,788
24/26/24 $2.060 -1.44% 26,725
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.170USD
Average target price
6.000USD
Spread / Average Target
+176.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LPCN Stock